Given the rapidly evolving landscape of Artificial Intelligence, one of the biggest hurdles tech leaders often come across is ...

Total revenues of $666.8 million for the full year 2024, representing a 16.5% year-over-year increase, indicating strong business growth. Cloud revenues grew by 28.6% year-over-year for the full year ...

Google Cloud began offering Vertex AI in 2021 to help developers, data scientists, and companies build and use generative AI models on one platform. Now, at Google Cloud Next, Google announced updates ...

Switzerland-based CRISPR Therapeutics (CRSP) and Boston, Massachusetts-based Vertex (VRTX) have been collaborating together since signing an initial agreement in 2015, with Vertex paying CRISPR $75m ...

Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...

Vertex Pharmaceuticals Incorporated is a $120bn market cap pharma giant with a successful CF franchise, growing revenues from $1bn in 2015 to $9.9bn in 2023. Vertex gained approval for its first ...

Google updated the documentation for the Google-Extended user agent, which publishers can use to control whether Google Gemini and Vertex use their data for training purposes or for grounding AI ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs), today announced a global, multi-target license and option agreement ...

Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly shy of expectations, top-line revenue growth was a significant beat. In ...

Orum Therapeutics (“Orum” or the “Company”), a clinical-stage private biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced a global, multi-target license ...